Overview
Encompass Health Corporation, based in the United States, operates primarily within the healthcare industry, specializing in post-acute services. As a leading provider of integrated healthcare services, it focuses on both facility-based and home-based patient care. The company runs an extensive network of inpatient rehabilitation hospitals and home health and hospice agencies across the U.S. Key projects and strategies revolve around expanding its rehabilitation services through the construction of additional hospitals and enhanced service offerings aimed at improving patient outcomes and operational efficiency. Encompass Health is dedicated to ensuring high-quality care, leveraging advanced technologies and specialized programs tailored to specific health conditions, thereby solidifying its position as a pivotal player in the post-acute healthcare sector.
AI+ Ask Fintel’s AI assistant about Encompass Health Corporation.
Thinking about good questions…
Basic Stats
The share price of Encompass Health Corporation as of September 5, 2025 is $125.58 / share. This is an increase of 3.14% from the prior week. The market cap (or net worth) of Encompass Health Corporation as of September 5, 2025 is $12,671.02 MM.
The Factor Analysis chart (below right) shows a view of Encompass Health Corporation from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 12,671.02 MM |
| EV | 15,841.54 MM |
| Shares Out. | 100.90 MM |
| Earnings Date | |
| EPS (TTM) | 5.18 |
| Dividend Yield | 0.61 % |
| Ex-Dividend Date | 2025-10-01 |
| Borrow Rate | 0.35 |
| Short Shares Avail. | 1.70 MM |
| Short Interest | 1.03 MM |
| Short Float | 1.04 % |
| Days to Cover | 2.11 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | 34.49 % |
| Volatility (1 yr) | 0.27 |
| Beta | 0.86 |
| Sharpe Ratio (1 yr) | 1.14 |
| Sortino Ratio (1 yr) | 1.89 |
| PE Ratio | 24.25 |
| Price/Book | 4.10 |
| Price/TBV | 18.60 |
| Book/Market | 0.24 |
| EBIT/EV | 0.05 |
| EBIT(3yr avg)/EV | 0.04 |
| ROA | 0.08 |
| ROE | 0.21 |
| ROIC | 0.09 |
| CROIC | -0.01 |
| OCROIC | 0.19 |
| Implied Volatility | 19.93 % |
| Put/Call OI Ratio | 0.63 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Encompass Health Corporation is $138.46. The forecasts range from a low of $126.25 to a high of $152.25. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Encompass Health Corporation. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-10-28 | Stephens & Co. | Overweight | Maintains | |
| 2022-10-28 | Raymond James | Strong Buy | Maintains | |
| 2022-09-21 | Credit Suisse | Outperform | Maintains | |
| 2022-08-24 | RBC Capital | Outperform | Maintains | |
| 2022-08-08 | Truist Securities | Buy | Maintains | |
| 2022-08-04 | Raymond James | Strong Buy | Maintains | |
| 2022-08-04 | BMO Capital | Outperform | Maintains | |
| 2022-08-04 | Barclays | Overweight | Maintains | |
| 2022-06-21 | Truist Securities | Buy | Maintains | |
| 2022-06-21 | Stephens & Co. | Overweight | Maintains | |
| 2022-06-17 | Raymond James | Strong Buy | Maintains | |
| 2022-06-10 | Credit Suisse | Outperform | Maintains | |
| 2022-06-08 | RBC Capital | Outperform | Maintains | |
| 2022-05-03 | RBC Capital | Outperform | Maintains | |
| 2022-05-02 | Raymond James | Strong Buy | Maintains | |
| 2022-04-29 | Credit Suisse | Outperform | Maintains | |
| 2022-02-07 | Raymond James | Strong Buy | Maintains | |
| 2021-11-03 | Mizuho | Buy | Maintains | |
| 2021-11-02 | Raymond James | Strong Buy | Maintains | |
| 2021-10-13 | Truist Securities | Buy | Maintains | |
| 2021-09-24 | UBS | Buy | Initiate | |
| 2021-08-02 | Raymond James | Outperform | Strong Buy | Upgrade |
| 2021-07-29 | RBC Capital | Outperform | Maintains | |
| 2021-07-29 | Credit Suisse | Outperform | Maintains | |
| 2021-07-02 | Deutsche Bank | Hold | Buy | Upgrade |
| 2021-04-29 | Raymond James | Outperform | Maintains | |
| 2021-01-28 | Credit Suisse | Outperform | Maintains | |
| 2020-11-30 | Raymond James | Outperform | Maintains | |
| 2020-11-23 | Barclays | Equal-Weight | Overweight | Upgrade |
| 2020-11-02 | Raymond James | Outperform | Maintains | |
| 2020-11-02 | Credit Suisse | Outperform | Maintains | |
| 2020-07-27 | Jefferies | Buy | Maintains | |
| 2020-05-01 | UBS | Buy | Maintains | |
| 2020-04-30 | Raymond James | Outperform | Maintains | |
| 2020-03-06 | UBS | Buy | Maintains | |
| 2020-03-06 | Deutsche Bank | Hold | Maintains | |
| 2020-03-05 | Stephens & Co. | Overweight | Maintains | |
| 2020-03-05 | Mizuho | Buy | Maintains | |
| 2020-03-05 | Baird | Outperform | Maintains | |
| 2020-02-10 | SunTrust Robinson Humphrey | Buy | Maintains | |
| 2020-02-10 | Mizuho | Buy | Maintains | |
| 2020-01-15 | Credit Suisse | Outperform | Maintains | |
| 2020-01-14 | BMO Capital | Outperform | Maintains | |
| 2020-01-10 | UBS | Buy | Maintains | |
| 2019-12-11 | Wells Fargo | Equal-Weight | Underweight | Downgrade |
| 2019-09-17 | Deutsche Bank | Hold | Initiate | |
| 2019-09-06 | Bank of America | Neutral | Buy | Upgrade |
| 2019-07-31 | Raymond James | Outperform | Maintains | |
| 2019-06-27 | BMO Capital | Outperform | Initiate | |
| 2019-05-30 | Barclays | Equal-Weight | Overweight | Upgrade |
| 2018-12-20 | Jefferies | Buy | Initiate | |
| 2018-12-14 | Barclays | Equal-Weight | Initiate | |
| 2018-11-16 | UBS | Buy | Initiate | |
| 2018-07-26 | Credit Suisse | Outperform | Outperform | Maintains |
| 2018-04-27 | Credit Suisse | Outperform | Outperform | Maintains |
| 2018-03-16 | Credit Suisse | Outperform | Outperform | Maintains |
| 2018-02-27 | Credit Suisse | Outperform | Outperform | Maintains |
| 2018-01-17 | Credit Suisse | Outperform | Initiate | |
| 2017-11-21 | William Blair | Outperform | Initiate | |
| 2017-11-02 | Mizuho | Neutral | Buy | Upgrade |
| 2017-08-31 | Stephens & Co. | Overweight | Initiate | |
| 2017-06-15 | KeyBanc | Sector Weight | Initiate | |
| 2017-02-14 | Craig-Hallum | Buy | Initiate | |
| 2017-02-13 | Craig-Hallum | Buy | Initiate | |
| 2017-01-04 | PiperJaffray | Neutral | Initiate | |
| 2016-11-09 | Mizuho | Buy | Neutral | Downgrade |
| 2016-08-01 | SunTrust Robinson Humphrey | Buy | Maintains | |
| 2016-06-27 | Barclays | Equal-Weight | Underweight | Downgrade |
| 2015-10-30 | SunTrust Robinson Humphrey | Buy | Maintains | |
| 2015-10-30 | Barclays | Equal-Weight | Maintains | |
| 2015-10-29 | Stifel Nicolaus | Buy | Hold | Downgrade |
| 2015-10-08 | Barclays | Equal-Weight | Maintains | |
| 2015-07-30 | Stifel Nicolaus | Buy | Maintains | |
| 2015-07-02 | JMP Securities | Market Perform | Outperform | Upgrade |
| 2015-06-12 | Deutsche Bank | Hold | Maintains | |
| 2015-06-10 | Wedbush | Neutral | Initiate | |
| 2015-06-08 | UBS | Neutral | Maintains | |
| 2015-02-26 | Barclays | Equal-Weight | Maintains | |
| 2015-01-08 | Barclays | Equal-Weight | Maintains | |
| 2014-07-30 | Barclays | Equal-Weight | Maintains | |
| 2014-07-29 | UBS | Neutral | Maintains | |
| 2014-07-29 | Mizuho | Buy | Maintains | |
| 2014-02-20 | Stifel Nicolaus | Buy | Maintains | |
| 2014-01-06 | Raymond James | Strong Buy | Market Perform | Downgrade |
| 2013-11-22 | Stifel Nicolaus | Buy | Maintains | |
| 2013-10-30 | Deutsche Bank | Hold | Maintains | |
| 2013-10-21 | Stifel Nicolaus | Buy | Maintains | |
| 2013-07-26 | Susquehanna | Positive | Maintains | |
| 2013-07-24 | Lazard | Buy | Maintains | |
| 2013-04-29 | Deutsche Bank | Hold | Maintains | |
| 2013-03-21 | Bank of America | Underperform | Maintains | |
| 2013-03-18 | UBS | Buy | Neutral | Downgrade |
| 2013-02-19 | UBS | Buy | Maintains | |
| 2013-02-01 | Deutsche Bank | Buy | Hold | Downgrade |
| 2012-10-29 | JMP Securities | Market Outperform | Market Perform | Downgrade |
| 2012-07-27 | Jefferies | Buy | Hold | Downgrade |
| 2012-07-03 | UBS | Buy | Initiate | |
| 2023-02-09 | Truist Securities | Buy | Maintains | |
| 2023-02-09 | Credit Suisse | Outperform | Maintains | |
| 2023-02-09 | Mizuho | Buy | Maintains | |
| 2023-02-08 | Stephens & Co. | Overweight | Maintains | |
| 2023-03-14 | Barclays | Equal-Weight | Initiate | |
| 2023-05-02 | RBC Capital | Outperform | Maintains | |
| 2023-04-04 | Barclays | Equal-Weight | Maintains | |
| 2023-05-01 | Mizuho | Buy | Maintains | |
| 2023-04-28 | B of A Securities | Buy | Maintains | |
| 2023-05-02 | Raymond James | Strong Buy | Maintains | |
| 2023-05-01 | Deutsche Bank | Buy | Maintains | |
| 2023-05-01 | Credit Suisse | Outperform | Maintains | |
| 2023-05-01 | Stephens & Co. | Overweight | Maintains | |
| 2023-06-29 | Stephens & Co. | Overweight | Overweight | Maintains |
| 2024-06-05 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2023-08-04 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2023-08-04 | Credit Suisse | Outperform | Outperform | Maintains |
| 2023-08-03 | Truist Securities | Buy | Buy | Maintains |
| 2023-08-03 | Raymond James | Strong Buy | Strong Buy | Maintains |
| 2023-08-03 | Mizuho | Buy | Buy | Maintains |
| 2023-08-03 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2023-07-20 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2023-08-08 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-02-09 | Truist Securities | Buy | Buy | Maintains |
| 2023-09-28 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-04-26 | Raymond James | Strong Buy | Strong Buy | Reiterate |
| 2024-05-22 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-01-16 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2024-02-09 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-03-06 | Barclays | Overweight | Initiate | |
| 2024-02-09 | Mizuho | Buy | Buy | Maintains |
| 2024-03-28 | Barclays | Overweight | Overweight | Maintains |
| 2024-04-25 | Barclays | Overweight | Overweight | Maintains |
| 2024-04-25 | Mizuho | Buy | Buy | Maintains |
| 2024-07-10 | Leerink Partners | Outperform | Initiate | |
| 2024-07-10 | Barclays | Overweight | Overweight | Maintains |
| 2024-07-15 | Truist Securities | Buy | Buy | Maintains |
| 2024-10-11 | Keybanc | Overweight | Initiate | |
| 2024-08-06 | Barclays | Overweight | Overweight | Maintains |
| 2025-02-07 | Barclays | Overweight | Overweight | Maintains |
| 2024-08-15 | Truist Securities | Buy | Buy | Maintains |
| 2025-08-14 | Truist Securities | Buy | Buy | Maintains |
| 2024-09-25 | UBS | Buy | Buy | Maintains |
| 2024-10-29 | Barclays | Overweight | Overweight | Maintains |
| 2024-10-29 | Keybanc | Overweight | Overweight | Maintains |
| 2024-09-26 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-02-11 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-08-06 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2024-10-30 | Truist Securities | Buy | Buy | Reiterate |
| 2024-10-30 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-08-08 | UBS | Buy | Buy | Maintains |
| 2024-10-14 | Truist Securities | Buy | Buy | Maintains |
| 2025-02-10 | Keybanc | Overweight | Overweight | Maintains |
| 2025-04-25 | Barclays | Overweight | Overweight | Maintains |
| 2025-04-28 | UBS | Buy | Buy | Maintains |
| 2025-04-25 | Keybanc | Overweight | Overweight | Maintains |
| 2025-04-28 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-04-28 | Truist Securities | Buy | Buy | Reiterate |
| 2025-06-05 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2025-08-06 | UBS | Buy | Buy | Maintains |
| 2025-05-27 | Keybanc | Overweight | Overweight | Maintains |
